WELCOME TO

ExpreS2ion Biotech

INVESTOR SITE

Financial Calendar

Latest press releases

Update on a new clinical Phase Ib trial for the RH5.1 blood-stage malaria vaccine

Non-regulatory pressrelease

Hørsholm, Denmark, July 21, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that University of Oxford has initiated the VAC080-study, a Phase Ib clinical trial to assess the safety and immunogenicity of the blood-stage Plasmodium falciparum malaria vaccine candidate RH5.1/Matrix-M in adults and infants living in Tanzania.

Read more

ExpreS2ion publishes video from company presentation at a Nordic investor event

Non-regulatory pressrelease

ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announces that a filmed company presentation by CEO Bent U. Frandsen at the LifeSci Advisors Nordic Biotech Summit investor event on June 29, 2021 is now available on the company’s Vimeo channel.

Read more

View all